Bessemer Group Inc. Has $698,000 Stock Position in SiBone $SIBN

Bessemer Group Inc. decreased its position in SiBone (NASDAQ:SIBN) by 11.9% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 37,105 shares of the company’s stock after selling 5,010 shares during the period. Bessemer Group Inc.’s holdings in SiBone were worth $698,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in SIBN. Calamos Advisors LLC acquired a new position in shares of SiBone in the 1st quarter valued at $918,000. Victory Capital Management Inc. lifted its position in SiBone by 55.0% in the 1st quarter. Victory Capital Management Inc. now owns 631,568 shares of the company’s stock valued at $8,861,000 after acquiring an additional 224,190 shares in the last quarter. Allianz Asset Management GmbH lifted its position in SiBone by 3.3% in the 1st quarter. Allianz Asset Management GmbH now owns 133,899 shares of the company’s stock valued at $1,879,000 after acquiring an additional 4,288 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new stake in SiBone in the 1st quarter valued at $162,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in SiBone in the 1st quarter valued at $683,000. Institutional investors and hedge funds own 98.11% of the company’s stock.

Insider Activity at SiBone

In other news, SVP Michael A. Pisetsky sold 3,329 shares of the business’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $15.64, for a total transaction of $52,065.56. Following the transaction, the senior vice president directly owned 258,352 shares in the company, valued at $4,040,625.28. The trade was a 1.27% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Anthony J. Recupero sold 3,833 shares of the company’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $15.62, for a total transaction of $59,871.46. Following the completion of the transaction, the insider owned 275,288 shares in the company, valued at approximately $4,299,998.56. This trade represents a 1.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 44,141 shares of company stock worth $680,628 over the last ninety days. Company insiders own 4.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on SIBN. Truist Financial cut their price objective on shares of SiBone from $22.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, October 15th. Wall Street Zen cut shares of SiBone from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SiBone in a research report on Wednesday, October 8th. Finally, Cantor Fitzgerald set a $25.00 price objective on shares of SiBone and gave the company an “overweight” rating in a research report on Monday, August 11th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $23.00.

SiBone Trading Down 2.1%

Shares of NASDAQ:SIBN opened at $14.83 on Friday. The stock has a market capitalization of $639.77 million, a PE ratio of -26.48 and a beta of 0.83. The company’s 50-day moving average price is $15.34 and its two-hundred day moving average price is $16.47. SiBone has a one year low of $11.70 and a one year high of $20.05. The company has a debt-to-equity ratio of 0.21, a current ratio of 8.38 and a quick ratio of 7.00.

SiBone (NASDAQ:SIBN) last released its quarterly earnings data on Monday, August 4th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.05. The company had revenue of $48.63 million for the quarter, compared to analyst estimates of $48.12 million. SiBone had a negative net margin of 12.83% and a negative return on equity of 14.20%. SiBone has set its FY 2025 guidance at EPS. On average, equities analysts forecast that SiBone will post -0.78 EPS for the current fiscal year.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.